Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

OBJECTIVES: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intended dose and time for the regimen, is commonly taken as a proxy for achieved RDI (aRDI), the actual individual dose and time for the regimen. Evaluating tRDI/aRDI mismatches is crucial to assess study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Lancia, Carlo, Anninga, Jakob, Spitoni, Cristian, Sydes, Matthew R., Whelan, Jeremy, Hogendoorn, Pancras C W, Gelderblom, Hans, Fiocco, Marta
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2019
Soggetti:
Oncology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549670/
https://ncbi.nlm.nih.gov/pubmed/31152023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-022980
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi